NovoCure Limited Class Action Lawsuit - NVCR

The filed complaint alleges that NovoCure Limited made materially false and/or misleading statements and/or failed to disclose that: (i) the Company concealed the true nature of the LUNAR study data, including that the study relied on a relatively small percentage of study participants that had been receiving standard of care therapy; (ii) as a result, the data was materially less reliable in terms of demonstrating clinical efficacy; (iii) the foregoing, once revealed, was reasonably likely to have a material negative impact on the Company’s regulatory prospects and operations; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times.

In order to be eligible to join the NVCR class action lawsuit, you must have incurred a loss on shares of NovoCure purchased during the class period listed above.

If you suffered a loss in NovoCure during the relevant time frame or pursuant to the relevant offering(s), you have until August 18, 2023 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.